Loading...
Kuruvilla, Tarun
Biography
Consultant Old Age Psychiatrist for the past 20 years
Consultant lead for the Glos memory assessment service - early diagnosis of dementia service
Visiting Prof at University of Gloucestershire
Clinical Director for Research at GHC
Community Settings Lead for the NIHR: SWC RRDN
Principle Investigator for numerous NIHR portfolio adopted dementia studies
14 results
Publication Search Results
Now showing 1 - 10 of 14
Publication Open Access Developing an amnestic mild cognitive impairment clinic(Royal College of Psychiatrists, 2025-05) Tyler, Laura; Wasunna-Smith, Brenda; Millward, Alice; Rees, Kerry; Kuruvilla, Tarun; Tyler, Laura; Wasunna-Smith, Brenda; Milward, Alice; Rees, Kerry; Kuruvilla, Tarun; Additional Professional Scientific and Technical; Medical and DentalNo abstract availablePublication Metadata only The Role of Hormone Replacement Therapy (HRT) for the Prevention of Alzheimer's Disease in Postmenopausal Women(Wiley, 2024-10-01) Littleford, Karla; Tyler, Laura; Dashwood, Mark; Reed, Hannah; Kuruvilla, Tarun; Tyler, Laura; Dashwood, Mark; Kuruvilla, Tarun; Medical and DentalAlzheimer's disease (AD) disproportionately affects women and, in 2022, was the leading cause of female deaths. It has major psychosocial, physical and economic impacts which will become more pronounced with an ageing population. Current treatments focus on symptom control and do not affect disease course. Emerging evidence suggests that the prescription of perimenopausal hormone replacement therapy (HRT) may prevent the development of AD. The objective of this narrative review is to synthesise and analyse relevant literature regarding HRT and AD prognosis in pre- and postmenopausal women to establish the current knowledge and provide a foundation for future research.Publication Metadata only Artificial intelligence as an aid to diagnosing dementia: an overview(Wiley, 2021-08-10) Dashwood, Mark; Churchhouse, Gabrielle; Young, Matilda; Kuruvilla, Tarun; Dashwood, Mark; Churchhouse, Gabrielle; Young, Matilda; Kuruvilla, Tarun; Medical and DentalArtificial intelligence (AI) is showing huge promise in assisting with early diagnosis of dementia, which would yield clear benefits in optimising the quality of life of those with dementia and their carers. In this review, the authors provide an overview of AI technology, its applications and implications for clinical practice. Consideration is given to ethical issues and future challenges.Publication Metadata only Dissociative identity disorder: areview of the diagnosis that divides(Wiley, 2024-05-14) Young, Matilda; Almaskati, Mazen; Vrabtchev, Svetlin; Kuruvilla, Tarun; Young, Matilda; Almaskati, Mazen; Vrabtchev, Svetlin; Kuruvilla, Tarun; Additional Professional Scientific and Technical; Medical and DentalThe diagnosis of dissociative identity disorder (DID) has been associated with controversy and remains an area of dispute among clinicians to this day. This review explores the evolution of the diagnosis and how it is currently described and understood in the International Classification of Diseases (ICD-11) and Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Also considered, are recent implications for clinical practice, treatment recommendations and the potential for any medicolegal issues to emerge.Publication Metadata only Aducanumab and disease modifying treatments for Alzheimer's disease(Wiley, 2021-08-10) Thomas, Emily; Wasunna-Smith, Brenda; Kuruvilla, Tarun; Thomas, Emily; Wasunna-Smith, Brenda; Kuruvilla, Tarun; Medical and DentalAducanumab has recently been licensed by the Food and Drug Administration (FDA) in the USA under its ‘accelerated approval’ pathway (to provide earlier access to treatments that fulfil an unmet need based on a surrogate endpoint) for treatment of Alzheimer's disease. This was a controversial decision, and the licence is subject to the outcome of further phase IV trials. Results will be eagerly anticipated, especially by the estimated 50 billion people worldwide currently living with dementia.1 The drugs success could pave the way for a new era in treatments at a time where existing therapies only offer symptomatic treatment to slow progression.Publication Metadata only Artificial intelligence as an aid to diagnosing dementia: an overview(Wiley, 2021-08-10) Dashwood, Mark; Churchhouse, Gabrielle; Young, Matilda; Kuruvilla, Tarun; Dashwood, Mark; Churchhouse, Gabrielle; Young, Matilda; Kuruvilla, Tarun; Medical and DentalArtificial intelligence (AI) is showing huge promise in assisting with early diagnosis of dementia, which would yield clear benefits in optimising the quality of life of those with dementia and their carers. In this review, the authors provide an overview of AI technology, its applications and implications for clinical practice. Consideration is given to ethical issues and future challenges.Publication Metadata only Blood-based biomarkers for Alzheimer's disease(Wiley, 2022-11-08) Chohan, Priyanka; Dashwood, Mark; Theodoulou, George; Reed, Hannah; Kuruvilla, Tarun; Dashwood, Mark; Kuruvilla, Tarun; Medical and DentalBlood-based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood-based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.Publication Metadata only Trauma-informed approach to managing behaviour in dementia(Wiley, 2024-05-14) Lewington, Kate; Berragan, Liz; Kuruvilla, Tarun; Lewington, Kate; Kuruvilla, Tarun; Nursing and Midwifery Registered; Medical and DentalCauses of behaviour that challenge in dementia are often thought to be due to reversible factors, such as a urine infection or disrupted sleep-wake cycle. In this review, the authors consider a definition of behaviour that challenges commonly cited causes and management models. Finally, recommendations for an alternative view and subsequent approach to managing behaviour that challenges are suggested.Publication Metadata only Lecanemab for Alzheimer's disease: new hope or another false dawn?(Wiley, 2023-02-09) Dashwood, Mark; Kuruvilla, Tarun; Dashwood, Mark; Kuruvilla, Tarun; Medical and DentalNo abstract availablePublication Open Access Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease A Randomized Clinical Trial(American Medical Association, 2020-02) Howard, Robert; Zubko, Olga; Bradley, Rosie; Harper, Emma; Pank, Lynn; O'Brien, John; Fox, Chris; Tabet, Naji; Livingston, Gill; Bentham, Peter; Kuruvilla, Tarun; Tait, Ellen; Moore, Lisa; Riley, Genevieve; Holt, Samantha; Zheng, Rui; Barber, Philip; Cartwright, Bethan; Harding, Chris; Romer, Jenny; Stithou, Suzanna; Harvey, Marelle; Kuruvilla, Tarun; Tait, Ellen; Moore, Lisa; Riley, Genevieve; Holt, Samantha; Zheng, Rui; Barber, Philip; Cartwright, Bethan; Harding, Chris; Romer, Jenny; Stithou, Suzanna; Harvey, Marelle; Medical and Dental; Admin and ClericalIMPORTANCE There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate. OBJECTIVE To determine whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild AD. DESIGN, SETTING, AND PARTICIPANTS Participants were recruited into a double-blind randomized clinical trial from May 23, 2014, to April 14, 2016, with 24 months of treatment and follow-up. This multicenter study in England and Scotland involved 32 National Health Service memory clinics within secondary specialist services for people with dementia. From 886 screened patients, 554 patients with a diagnosis of mild AD (Standardised Mini-Mental State Examination [sMMSE] score 24) were randomized. INTERVENTIONS Participants were randomly allocated 1:1:1 in a semifactorial design to receive minocycline (400 mg/d or 200 mg/d) or placebo for 24 months. MAIN OUTCOMES AND MEASURES Primary outcome measures were decrease in sMMSE score and Bristol Activities of Daily Living Scale (BADLS), analyzed by intention-to-treat repeated-measures regression. RESULTS Of 544 eligible participants (241 women and 303 men), the mean (SD) age was 74.3 (8.2) years, and the mean (SD) sMMSE score was 26.4 (1.9). Fewer participants completed 400-mg minocycline hydrochloride treatment (28.8% [53 of184]) than 200-mg minocycline treatment (61.9% [112 of 181]) or placebo (63.7% [114 of 179]; P < .001), mainly because of gastrointestinal symptoms (42 in the 400-mg group, 15 in the 200-mg group, and 10 in the placebo group; P < .001), dermatologic adverse effects (10 in the 400-mg group, 5 in the 200-mg group, and 1 in the placebo group; P = .02), and dizziness (14 in the 400-mg group, 3 in the 200-mg group, and 1 in the placebo group; P = .01). Assessment rates were lower in the 400-mg group: 68.4% (119 of 174 expected) for sMMSE at 24 months compared with 81.8% (144 of 176) for the 200-mg group and 83.8% (140 of 167) for the placebo group. Decrease in sMMSE scores over 24 months in the combined minocycline group was similar to that in the placebo group (4.1 vs 4.3 points). The combined minocycline group had mean sMMSE scores 0.1 points higher than the placebo group (95% CI, −1.1 to 1.2; P = .90). The decrease in mean sMMSE scores was less in the 400-mg group than in the 200-mg group (3.3 vs 4.7 points; treatment effect = 1.2; 95% CI, −0.1 to 2.5; P = .08). Worsening of BADLS scores over 24 months was similar in all groups: 5.7 in the 400-mg group, 6.6 in the 200-mg group, and 6.2 in the placebo groups (treatment effect for minocycline vs placebo = –0.53; 95% CI, −2.4 to 1.3; P = .57; treatment effect for 400 mg vs 200 mg of minocycline = –0.31; 95% CI, −0.2 to 1.8; P = .77). Results were similar in different patient subgroups and in sensitivity analyses adjusting for missing data. CONCLUSIONS AND RELEVANCE Minocycline did not delay the progress of cognitive or functional impairment in people with mild AD during a 2-year period. This study also found that 400 mg of minocycline is poorly tolerated in this population. TRIAL REGISTRATION isrctn.org Identifier: ISRCTN16105064